Intriguingly, these SHIP-1 activating compounds increased apoptosis of multiple myeloma cells in vitro and when used in combination with bortezomib (an established multiple myeloma treatment) proved more effective at inhibiting cancer cell proliferation than bortezomib alone (Kennah et al., 2009). The gene discussed is INPP5D; the disease is AL amyloidosis.